Now This Growth Stock Is Getting Attractive
The Motley Fool
Published Nov 12, 2018 08:09
Updated Nov 12, 2018 08:45
Jamieson Wellness (TSX:JWEL) stock has corrected about 15% since it reported its third-quarter results last Tuesday. However, the stock was actually weak earlier than that. Specifically, after it peaked in late September, the stock has lost about 30% of its value from about $27 to below $19 per share.
The business
Jamieson manufactures, distributes, and markets branded natural healthcare products, including vitamins, minerals, and supplements.
It has a number one position in Canada with a market share of 25% at food, drug, and mass stores, such as Superstore and London Drugs.
Jamieson operates in two business segments. Its branded segment offers a diversified range of premium products across multiple distribution channels. Last year, this segment contributed to 79% of revenue and 86% of adjusted EBITDA.
Its strategic partners segment are co-manufacturing partnerships with select blue-chip consumer health companies and retailers around the world, aiming to leverage infrastructure and reduce costs. Last year, this segment contributed to 21% of revenue and 14% of adjusted EBITDA.
Q3 results
Here are some key metrics compared to the same period in 2017:
| Q3 2017 | Q3 2018 | Change | |
| Revenue | $80.1 million | $83.1 million | 3.7% |
| Earnings from operations | $11.3 million | $12.7 million | 12.5% |
| Adjusted net income | $7.8 million | $8.9 million | 13.6% |
| Adjusted EBITDA | $16.1 million | $17.9 million | 10.7% |
| Adjusted diluted earnings per share | $0.20 | $0.22 | 13.6% |
Year over year, Jamieson’s gross profit margin and operating margin improved from 33% to 33.2% and 14.1% to 15.3%, respectively.
Get The App
Jamieson’s nine-month results
Here are some key metrics compared to the same period in 2017:
| Q1-Q3 2017 | Q1-Q3 2018 | Change | |
| Revenue | $216.3 million | $230.3 million | 6.5% |
| Earnings from operations | $30 million | $33 million | 10% |
| Adjusted net income | $17.8 million | $21.5 million | 20.7% |
| Adjusted EBITDA | $42.6 million | $44.7 million | 4.8% |
| Adjusted diluted earnings per share | $0.45 | $0.54 | 20.7% |
Recent international growth developments
Jamieson products are available in more than 40 countries around the world. Recently, Jamieson made advancements in its growth strategy in China. Instead of only selling its products via an online store, it obtained the right to sell in physical stores as well. It’s also setting up an office and warehouse in Shanghai.
Furthermore, after signing a five-year partnership agreement, Jamieson’s products will begin selling this month in MedPlus, India’s second-largest pharmacy chain. MedPlus has 1,500 retail locations and plans to more than triple its locations by 2023.
Investor takeaway
Jamieson is a attractive for double-digit growth at an estimated 2018 P/E of about 21.8.
Fool contributor Kay Ng has no position in any of the stocks mentioned.
This Article Was First Published on The Motley Fool
Written By: The Motley Fool
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.